Sodium–glucose cotransporter-2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RA) are indicated independently of glycemic control in patients with T2D who have or are at risk of ASCVD, CKD, and/or heart failure (HF). This evidence concerns the gene GLP1R and hydrops fetalis.